New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues ...
Breadcrumb Trail Links GlobeNewswire Author of the article: Published Jul 30, 2024 • 19 minute read Lecanemab 36 Month CDR-SB GNW Article content 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab …